IMVT Stock Up on Upbeat Data From Graves’ Disease Study of Batoclimab
ZacksImmunovant stock rises on mid-stage study data of batoclimab for Graves’ Disease, showing superior efficacy compared to anti-thyroid drug therapy options.
Immunovant stock rises on mid-stage study data of batoclimab for Graves’ Disease, showing superior efficacy compared to anti-thyroid drug therapy options.